IDC:内地次季可穿戴设备出货量升34% 小米(01810.HK)市占险胜华为
调研机构IDC《中国可穿戴设备市场季度跟踪报告》显示,2019年第二季度中国可穿戴设备市场出货量为2,307万台,按年增长34.3%。基础可穿戴设备(不支持第三方应用的可穿戴设备)出货量为1,846万台,按年增长31.9%,智能可穿戴设备出货量为461万台,按年增长45%。
报告显示,小米(01810.HK)次季出货量528.9万台,按年升42.5%,该季在内地市场份额达22.9%(居首)、华为次季出货量506.9万台,按年升1.89倍,该季在内地市场份额达22%(处第二位)、第三位是苹果公司,次季出货量317.1万台,按年升43.3%,该季在内地市场份额达13.8%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.